LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

Search

Harmony Biosciences Holdings Inc

Chiusa

SettoreSettore sanitario

34.23 -2.53

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.04

Massimo

35.49

Metriche Chiave

By Trading Economics

Entrata

11M

51M

Vendite

39M

239M

P/E

Media del settore

11.36

110.024

EPS

1.08

Margine di Profitto

21.242

Dipendenti

268

EBITDA

14M

73M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+36.76% upside

Dividendi

By Dow Jones

Utili prossimi

24 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

387M

2.1B

Apertura precedente

36.76

Chiusura precedente

34.23

Notizie sul Sentiment di mercato

By Acuity

53%

47%

289 / 351 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 feb 2026, 23:47 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

19 feb 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19 feb 2026, 23:39 UTC

Acquisizioni, Fusioni, Takeovers

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19 feb 2026, 23:38 UTC

Utili

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19 feb 2026, 23:38 UTC

Utili

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19 feb 2026, 23:38 UTC

Utili

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19 feb 2026, 23:37 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19 feb 2026, 23:34 UTC

Utili

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19 feb 2026, 23:34 UTC

Utili

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19 feb 2026, 23:33 UTC

Utili

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19 feb 2026, 23:33 UTC

Utili

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19 feb 2026, 22:13 UTC

Discorsi di Mercato

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19 feb 2026, 22:08 UTC

Utili

Fairfax Financial 4Q Rev $8.11B >FFH.T

19 feb 2026, 22:07 UTC

Utili

Eldorado Gold 4Q EPS $1.19 >ELD.T

19 feb 2026, 22:06 UTC

Utili

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19 feb 2026, 22:05 UTC

Utili

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19 feb 2026, 22:05 UTC

Utili

Eldorado Gold 4Q Rev $577.2M >ELD.T

19 feb 2026, 22:04 UTC

Utili

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19 feb 2026, 22:04 UTC

Utili

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19 feb 2026, 21:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

19 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

19 feb 2026, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

19 feb 2026, 21:43 UTC

Utili

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19 feb 2026, 21:42 UTC

Acquisizioni, Fusioni, Takeovers

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19 feb 2026, 21:42 UTC

Utili

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19 feb 2026, 21:41 UTC

Utili

Correct: St Barbara 1H Net Loss A$249,000

19 feb 2026, 21:40 UTC

Utili

St Barbara 1H Net Loss A$249 Million

19 feb 2026, 21:39 UTC

Utili

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19 feb 2026, 21:37 UTC

Utili

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19 feb 2026, 21:37 UTC

Utili

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Confronto tra pari

Modifica del prezzo

Harmony Biosciences Holdings Inc Previsione

Obiettivo di Prezzo

By TipRanks

36.76% in crescita

Previsioni per 12 mesi

Media 48.25 USD  36.76%

Alto 55 USD

Basso 42 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Harmony Biosciences Holdings Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

4

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

29.8 / N/ASupporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Very Strong Bearish Evidence

Sentiment

By Acuity

289 / 351 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat